## What BPC-157 is
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (gastric peptide fragment). BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric protective protein. As of 2026, only 3 published human studies exist (all pilot-scale with <30 subjects), but 500+ preclinical studies show tissue healing effects. A 2025 IV safety study (up to 20mg) in healthy adults showed no adverse events across cardiac, hepatic, and renal biomarkers. It has a molecular formula C62H98N16O22, mass 1419.53 Da. Its published amino-acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Common synonyms in the literature include Body Protection Compound-157, Bepecin, and PL 14736. This SKU is a co-formulated blend that also contains TB-500 (Thymosin Beta-4 Fragment) in the same vial — for research groups that want to combine the two under a single reconstitution.
## What it's studied for
Investigation of BPC-157 to date is primarily preclinical, with the majority of citations concentrated in animal models and in-vitro assays rather than randomized controlled human trials. Published work referencing BPC-157 spans In-vitro cell culture studies: BPC-157 has been examined in fibroblast, endothelial cell, and smooth muscle cell lines to observe effects on cell migration, proliferation, oxidative stress responses, and signaling pathway activation. These controlled experiments provide mechanistic insight at the cellular level but do not fully represent complex whole-organism physiology, Tendon and ligament models: Rodent studies have investigated BPC-157 in surgically induced or chemically induced tendon injuries, including Achilles tendon transection models. Researchers have reported observations on healing timelines, collagen fiber alignment, tensile strength measurements, and histological markers of tissue maturation, and Musculoskeletal injury research: Animal studies have explored BPC-157 in crushed muscle and transected muscle paradigms, with observations reported on fibroblast survival, cell migration, biomechanical recovery metrics, and regeneration markers. Proposed mechanisms in the literature include VEGF and angiogenesis: upregulates VEGF expression in vivo, activates VEGFR2 receptors on endothelial cells, triggers Akt-eNOS pathway phosphorylation and Nitric oxide modulation: enhances endothelial NOS (eNOS) activity via Src-Cav-1-eNOS pathways, influences NO synthase activity and vascular tone. None of this material describes therapeutic outcomes in humans, and BioInfinity does not sell, market, or provide dosing guidance for BPC-157 outside laboratory research.
## Laboratory handling — storage and reconstitution
Lyophilized BPC-157 arrives as a fluffy off-white solid inside a sealed sterile vial. Because it ships as a lyophilized peptide (1419.53 Da), the powder is best stored between 2–8 °C prior to reconstitution and returned to −20 °C in aliquots for long-term storage post-reconstitution. Reconstitution is typically performed with bacteriostatic water (0.9 % benzyl alcohol preserved) rather than sterile water because the preservative extends solution stability once the vial has been punctured. Warming the reconstituted solution to room temperature before drawing helps redissolve any peptide that has settled against the vial wall. Avoid repeated freeze–thaw cycles: for peptides in this molecular-weight range (1419.53 Da), freeze–thaw stress is one of the most common causes of loss-of-purity between batches.
## How this batch is verified
Every batch of BPC-157 ships with a batch-specific Certificate of Analysis produced by an ISO-accredited third-party analytical laboratory. Reversed-phase HPLC confirms the assay against the expected 1419.53 Da mass (C62H98N16O22); mass spectrometry validates the exact monoisotopic mass; endotoxin (LAL) testing confirms bacterial-contamination limits appropriate for laboratory research; and residual-solvent panels confirm the manufacturing pipeline. The lot number on the outer label matches the COA on the public /coa-library page — every purity claim is independently verifiable before you open the vial.
## Related research
For the full mechanistic profile, published references, and constraint notes on BPC-157, see the [BPC-157 research page](/research/bpc-157). All references cited on that page are peer-reviewed primary literature.
**Research use only.** BPC-157 & TB-500 is sold strictly for in-vitro and animal research. It is not a drug, food, supplement, or cosmetic and is not intended for human or veterinary consumption. No statements on this page describe or imply any therapeutic effect.
Researchers should refer to peer-reviewed publications for primary sources on this compound. BPC-157 & TB-500 is sold strictly for laboratory research use and is not intended for human or veterinary use.
